Study Title
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma (NCT01874054)
Trial Description
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.
This trial is sponsored by Seattle Genetics. [1]
Study Data
- Condition: Hodgkin lymphoma
- Interventions:
- Drugs used in this trial
- brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- bendamustine (Treanda®; Teva Pharmaceuticals)
- Drugs used in this trial
- Phase: I & II
- Enrollment: 55
- Start: June 2013
- Estimated Completion: December 2017
- Last verified: March 2015
Study Schematic
Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
